Document Detail

Lower concentrations of thrombin-antithrombin complex (TAT) correlate to higher recanalisation rates among ischaemic stroke patients treated with t-PA.
MedLine Citation:
PMID:  19806263     Owner:  NLM     Status:  In-Process    
An elevated concentration of the thrombin-antithrombin complex (TAT) has been associated with high mortality rates and poor outcome in ischaemic stroke patients treated with tissue plasminogen activator (t-PA). Moreover, antithrombin drugs have been tested in combination with t-PA in the acute phase of ischaemic stroke to increase treatment efficacy. We aimed to study whether poor outcome associated with TAT among ischaemic stroke patients treated with t-PA could be due to the effects of this complex on recanalisation rates of the middle cerebral artery (MCA) and on haemorrhagic transformation. The TAT levels of 89 patients having a proximal MCA occlusion were measured by ELISA, and the patients were then treated with t-PA. Complete recanalisation was diagnosed by transcranial Doppler (TCD) at 1, 2 and 6 hours post-t-PA infusion and haemorrhagic transformation was identified by computed tomography (CT). Lower levels of TAT were associated with better recanalisation rates at all time-points (1 hour: OR = 24.8 95% CI 1.4-434.8, p = 0.028; 2 hours: OR = 6.3 95% CI 1.5-27, p = 0.014; 6 hours: OR = 6.4 95% CI 1.5-26.5, p = 0.011) after adjustment for stroke risk factors. However, no correlation was found between TAT concentration and haemorrhagic transformation. The elevated mortality rates previously observed in patients with high levels of TAT might have been due to revascularisation resistance. Low levels of TAT are not associated with an increase in haemorrhagic complications after t-PA, indicating that the combination of thrombin blockers and t-PA could be a safe and effective treatment for ischaemic stroke in the future.
Israel Fernandez-Cadenas; Maite Mendioroz; Josep Munuera; José Alvarez-Sabin; Alex Rovira; Adoracion Quiroga; Natalia Corbeto; Marta Rubiera; Pilar Delgado; Anna Rosell; Marc Ribó; Carlos A Molina; Joan Montaner
Related Documents :
2208883 - I-123 hydroxyiodobenzyl propanediamine (hipdm) cerebral blood flow imaging demonstratin...
16914403 - Preadmission antithrombotic treatment and stroke severity in patients with atrial fibri...
6211133 - Clinical evaluation of piperacillin with observations on penetrability into cerebrospin...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Thrombosis and haemostasis     Volume:  102     ISSN:  0340-6245     ISO Abbreviation:  Thromb. Haemost.     Publication Date:  2009 Oct 
Date Detail:
Created Date:  2009-10-06     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7608063     Medline TA:  Thromb Haemost     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  759-64     Citation Subset:  IM    
Neurovascular Research Laboratory, Neurovascular Unit. Neurology Service, Departamento de medicina, Vall d'Hebron Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Real-life anticoagulation treatment of atrial fibrillation after catheter ablation: Possible overtre...
Next Document:  Repletion of factor XIII following cardiopulmonary bypass using a recombinant A-subunit homodimer. A...